High Grade Serous Carcinoma
14
2
3
3
Key Insights
Highlights
Success Rate
43% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
28.6%
4 terminated out of 14 trials
42.9%
-43.6% vs benchmark
0%
0 trials in Phase 3/4
100%
3 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (14)
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer
A Study to Investigate LYL797 in Adults With Solid Tumors
A Biomarker Screening Protocol for Participants With Solid Tumors
Multi-layer Data to Improve Diagnosis, Predict Therapy Resistance and Suggest Targeted Therapies in HGSOC
Combination of Olaparib and Navitoclax in Women with HGSC and TNBC
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
PET/MRI in Endometrial Cancer
Role of the ATP7A Transporter in Ovarian Cancer
BrUOG 390: Neoadjuvant Treatment With Talazoparib
A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma
Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy
Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients
Non-coding RNA in the Exosome of the Epithelia Ovarian Cancer